195 related articles for article (PubMed ID: 21159668)
1. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
2. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
Tanaka H; Hashimoto N
Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
[TBL] [Abstract][Full Text] [Related]
3. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
4. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs.
Li GR; Wang HB; Qin GW; Jin MW; Tang Q; Sun HY; Du XL; Deng XL; Zhang XH; Chen JB; Chen L; Xu XH; Cheng LC; Chiu SW; Tse HF; Vanhoutte PM; Lau CP
Circulation; 2008 May; 117(19):2449-57. PubMed ID: 18458165
[TBL] [Abstract][Full Text] [Related]
5. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
[TBL] [Abstract][Full Text] [Related]
6. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
7. Accessory Kvbeta1 subunits differentially modulate the functional expression of voltage-gated K+ channels in mouse ventricular myocytes.
Aimond F; Kwak SP; Rhodes KJ; Nerbonne JM
Circ Res; 2005 Mar; 96(4):451-8. PubMed ID: 15662035
[TBL] [Abstract][Full Text] [Related]
8. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
9. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
10. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
11. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
Fedida D; Eldstrom J; Hesketh JC; Lamorgese M; Castel L; Steele DF; Van Wagoner DR
Circ Res; 2003 Oct; 93(8):744-51. PubMed ID: 14500335
[TBL] [Abstract][Full Text] [Related]
12. The ultrarapid and the transient outward K(+) current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation.
Brandt MC; Priebe L; Böhle T; Südkamp M; Beuckelmann DJ
J Mol Cell Cardiol; 2000 Oct; 32(10):1885-96. PubMed ID: 11013132
[TBL] [Abstract][Full Text] [Related]
13. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of cardiac potassium channels.
Li GR; Dong MQ
Adv Pharmacol; 2010; 59():93-134. PubMed ID: 20933200
[TBL] [Abstract][Full Text] [Related]
15. Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
Gao Z; Sun H; Chiu SW; Lau CP; Li GR
Br J Pharmacol; 2005 Feb; 144(4):595-604. PubMed ID: 15678082
[TBL] [Abstract][Full Text] [Related]
16. Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain.
Wu HJ; Wu W; Sun HY; Qin GW; Wang HB; Wang P; Yalamanchili HK; Wang J; Tse HF; Lau CP; Vanhoutte PM; Li GR
J Mol Cell Cardiol; 2011 Dec; 51(6):966-73. PubMed ID: 21906601
[TBL] [Abstract][Full Text] [Related]
17. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
Tamargo J; Caballero R; Gómez R; Delpón E
Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
[TBL] [Abstract][Full Text] [Related]
18. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
20. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both.
Caballero R; de la Fuente MG; Gómez R; Barana A; Amorós I; Dolz-Gaitón P; Osuna L; Almendral J; Atienza F; Fernández-Avilés F; Pita A; Rodríguez-Roda J; Pinto A; Tamargo J; Delpón E
J Am Coll Cardiol; 2010 May; 55(21):2346-54. PubMed ID: 20488306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
